Hos patienter med massive tumorer, omfattende en undergruppe af patienter med bryst - og ovariecancer, behandlet med en dosis på 50 mg/ m2/ cyklus med livstidskumulative anthracyclin doser på op til 1. 532 mg/ m2, var hyppigheden af klinisk betydende kardielle funktionsfejl lav.
In patients with solid tumours, including a subset of patients with breast and ovarian cancers, treated at a dose of 50 mg/ m2/ cycle with lifetime cumulative anthracycline doses up to 1,532 mg/ m2, the incidence of clinically significant cardiac dysfunction was low.